Yuhan's Lazertinib combination therapy sales surpass $300M for the first time
Predicted impact: Low· Actual: +10.2% vs sector, volume 2.7× normal (5 trading days)
Lazertinib combined sales above $300M were already reported in the past 14 days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.